Researchers developed a chemogenetic system combining caffeine, nanobodies, and CRISPR to control gene editing. The approach ...

The global cell and gene therapy market is experiencing explosive growth. Key growth factors include rising chronic/genetic disease prevalence, advancements in gene editing (CRISPR) and viral vectors, ...

Gene editing is now reaching the mainstream, ushering in a new era of genetic manipulation. Traditionally, inserting or deleting entire genes, regulating their expression, and altering specific ...

A new gene-editing technique enables the correction of multiple genetic mutations simultaneously, transforming the prospects for millions living with complex inherited diseases, such as cystic ...

Scientists have corrected gene mutations in mice causing an ultra-rare disease by editing DNA directly in the brain with a single injection, a feat with profound implications for patients with ...

Biotech companies that use gene editing tools can face intellectual property (IP) challenges during commercialization. That’s the view of Austin Hallgren, strategic account manager for bioproduction ...

Artificial intelligence (AI) is known for enabling deeper insights into drug development, identifying patterns and molecules that may otherwise go unnoticed. Now it is poised to make similar ...

C&EN’s award-winning podcast Inflection Point leans on our 100-year archive to trace headline topics in science today back to their disparate and surprising roots. In each episode, we explore three ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...